Clinical Trials Sponsored by Covis Pharma S.à.r.l.

Total 71 results

Covis Pharma S.à.r.l.

Completed

A Study of the Safety and Efficacy of Ciclesonide in the Treatment of Non-hospitalized COVID-19 Patients

COVID-19

United States
Covis Pharma S.à.r.l.

Completed

Efficacy and Safety of Vascana® in Subjects With Secondary Raynaud's Phenomenon

Raynaud's Phenomenon Secondary to Connective Tissue Disease

United States
Covis Pharma S.à.r.l.

Completed

Comparison Between Systemic Exposure to Ciclesonide Nasal Spray, Ciclesonide HFA Nasal Aerosol and Orally Inhaled Ciclesonide (BY9010/M1-422)

Allergic Rhinitis

United States
UCB Biopharma S.P.R.L.

Completed

A Study to Assess the Efficacy, Safety and Tolerability of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (MyCIDPchoice)

Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

United States, Belgium, Denmark, France, Germany, Netherlands, Spain, United Kingdom
UCB Biopharma S.P.R.L.

Completed

A Study to Evaluate the Efficacy and Safety of Different Doses of Bimekizumab in Subjects With Active Ankylosing Spondylitis (BE AGILE)

Ankylosing Spondylitis

United States, Bulgaria, Canada, Czechia, Germany, Hungary, Poland, Russian Federation, Spain, Ukraine
UCB Biopharma S.P.R.L.

Terminated

Study to Evaluate the Long-term Safety and Tolerability of USL261 in Patients With Seizure Clusters

Epilepsy

United States, Australia, Hungary, Israel, Poland, Ukraine, Spain, Canada, Germany, New Zealand
UCB Biopharma S.P.R.L.

Completed

A Study to Test the Efficacy and Safety of Certolizumab Pegol in Japanese Subjects With Moderate to Severe Chronic Psoriasis

Moderate to Severe Psoriasis | Generalized Pustular Psoriasis and Erythrodermic Psoriasis

Japan
UCB Biopharma S.P.R.L.

Completed

A Study to Evaluate Safety and Tolerability of Single Ascending Doses of Rozanolixizumab Administered by Subcutaneous Infusion in Healthy Japanese, Chinese and Caucasian Study Participants

Healthy-volunteers

United Kingdom
UCB Biopharma S.P.R.L.

Terminated

A Pharmacokinetic Study of Padsevonil in Study Participants With Either Normal or Moderately Impaired Hepatic Function

Impaired Hepatic Function | Healthy Study Participants

United States
UCB Biopharma S.P.R.L.

Terminated

A Study to Test the Cardiac Effects of Padsevonil in Healthy Study Participants

Healthy Study Participants

United Kingdom
UCB Biopharma S.P.R.L.

Completed

A Study to Evaluate the Safety and Tolerability of Intravenous Brivaracetam (BRV) as Replacement for Oral Brivaracetam in Japanese Subjects >=16 Years of Age With Partial Seizures With or Without Secondary Generalization

Epilepsy | Partial Seizures With or Without Secondary Generalization

Japan
UCB Biopharma S.P.R.L.

Completed

A Study in Participants With Epilepsy, to Evaluate the Pharmacokinetics, Safety and Tolerability of Oxcarbazepine on Padsevonil

Epilepsy

Bulgaria, Netherlands
UCB Biopharma S.P.R.L.

Completed

A First-In-Human Study With a Single Ascending Dose of UCB7858 in Healthy Volunteers

Healthy Volunteers

United Kingdom
UCB Biopharma S.P.R.L.

Completed

Study to Evaluate the Impact of Using Wearable Devices in Addition to Standard Clinical Practice on Parkinson´s Subject Symptoms Management

Parkinson´s Disease

United States
UCB Biopharma S.P.R.L.

Completed

A Study to Test the Safety, Pharmacokinetics, and Pharmacodynamics of Single Ascending Intravenous Doses of UCB0107 in Healthy Male Subjects

Healthy Male Volunteers

Germany
UCB Biopharma S.P.R.L.

Completed

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of UCB0942 in Healthy Japanese and Caucasian Subjects

Healthy Japanese and Caucasian Subjects

United Kingdom
UCB Biopharma S.P.R.L.

Completed

A Study to Investigate the Bioequivalence of Lacosamide Tablet (200mg) and Syrup (10mg/ml) in Healthy Chinese Male Subjects

Healthy Male Volunteers

China
UCB Biopharma S.P.R.L.

Completed

A Study to Demonstrate the Bioequivalence of Lacosamide Tablets and Dry Syrup in Healthy Male Japanese Subjects

Healthy Volunteers

United Kingdom
UCB Biopharma S.P.R.L.

Completed

A Study to Evaluate the Dose Response Based on the Efficacy, Safety and Tolerability of Bimekizumab in Subjects With Active Psoriatic Arthritis Which is a Type of Inflammatory Arthritis (BE ACTIVE)

Psoriatic Arthritis

United States, Czechia, Germany, Hungary, Poland, Russian Federation
UCB Biopharma S.P.R.L.

Completed

A Study to Test the Safety, and Tolerability of Padsevonil in Healthy Male Japanese Study Participants

Healthy Japanese Participants

Japan
UCB Biopharma S.P.R.L.

Completed

A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus

Systemic Lupus Erythematosus (SLE)

United States, Bulgaria, Chile, Colombia, Germany, Hungary, Mexico, Peru, Poland, Romania, Russian Federation, Spain, Ukraine
UCB Biopharma S.P.R.L.

Completed

A Study to Evaluate the Antibody Response of Influenza Vaccination Following Concomitant Exposure to Bimekizumab in Healthy Subjects

Healthy Volunteers

United States
UCB Biopharma S.P.R.L.

Completed

An Efficacy and Safety Study of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO) (CIMPASI-1)

Psoriasis | Plaque Psoriasis

United States, Canada, Czechia, Germany, Hungary
UCB Biopharma S.P.R.L.

No longer available

Compassionate Use Program With Lacosamide in Patients With Partial-onset or Generalized Tonic-clonic Seizures

Epilepsies, Partial
UCB Biopharma S.P.R.L.

Completed

Study to Test the Safe and Effective Use of an e-Device for the Self-injection of Certolizumab Pegol Solution by Subjects With Moderate to Severe Active Rheumatoid Arthritis, Active Ankylosing Spondylitis, Active Psoriatic Arthritis, or Moderately to Severely Active Crohn's Disease

Moderate and Severe Active Rheumatoid Arthritis | Active Psoriatic Arthritis | Active Ankylosing Spondylitis | Moderately to Severely Active Crohn's Disease

United States
UCB Biopharma S.P.R.L.

Completed

Study to Evaluate the Safety and Efficacy of USL261 in Patients With Increased Bouts of Seizure Activity in the EMU

Epilepsy

United States, Spain, Belgium, Germany, Lithuania, Czechia, Austria, Australia
UCB Biopharma S.P.R.L.

Terminated

Study to Evaluate the Safety and Efficacy of USL261 (Intranasal Midazolam) in Patients With Seizure Clusters (ARTEMIS1)

Epilepsy

United States, Australia, Canada, Germany, Hungary, Israel, Italy, New Zealand, Poland, Spain, Ukraine
UCB Biopharma S.P.R.L.

Terminated

A Long-term Safety and Tolerability Study of USL261 in Patients With Seizure Clusters

Epilepsy

United States
UCB Biopharma S.P.R.L.

Completed

A Study to Evaluate the Efficacy and Safety of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO) (CIMPASI-2)

Psoriasis | Plaque Psoriasis

United States, Austria, Canada, Poland
UCB Biopharma S.P.R.L.

Terminated

A Phase 2 Study of Radiprodil in Subjects With Drug-resistant Infantile Spasms (IS)

Infantile Spasms (IS)

France
UCB Biopharma S.P.R.L.

Completed

A Study to Investigate the Bioequivalence of Lacosamide 200mg Administered as Intravenous Solution and Oral Tablet in Healthy Chinese Male Subjects

Healthy Male Chinese Volunteers

China
UCB Biopharma S.P.R.L.
Pharm Research Associates (UK) Ltd.

Completed

Study to Look at How Effective Briviact is as add-on Treatment for Patients With Epilepsy With Partial Onset Seizures (BASE)

Epilepsy With POS With or Without Secondary Generalization

Denmark, Germany, Hungary, Ireland, Italy, Netherlands, Norway, Spain, United Kingdom
UCB Biopharma S.P.R.L.

Completed

Study to Test the Efficacy and Safety of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adults With Drug-resistant Epilepsy (ARISE)

Focal-Onset Seizures | Drug-resistant Epilepsy

United States, Australia, Belgium, Bulgaria, Canada, Czechia, France, Germany, Hungary, Italy, Japan, Lithuania, Mexico, Poland, Portugal, Slovakia, Spain, Turkey, United Kingdom
UCB Biopharma S.P.R.L.

Completed

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Intravenous Brivaracetam in Subjects >= 1 Month to < 16 Years of Age With Epilepsy

Epilepsy

United States, Czechia, Germany, Hungary, Italy, Mexico, Spain
UCB Biopharma S.P.R.L.

Completed

Study to Test the Safety, Tolerability and Efficacy of UCB7665 in Subjects With Moderate to Severe Myasthenia Gravis

Myasthenia Gravis

United States, Belgium, Canada, Czechia, Denmark, Germany, Spain
UCB Biopharma S.P.R.L.

Completed

Efficacy and Safety Study of Certolizumab Pegol (CZP) Versus Active Comparator and Placebo in Subjects With Plaque Psoriasis (PSO) (CIMPACT)

Psoriasis | Plaque Psoriasis

United States, Bulgaria, Czechia, France, Germany, Hungary, Netherlands, Poland, United Kingdom
UCB Biopharma S.P.R.L.

Completed

Study to Evaluate the Effect of Coadministered Erythromycin on the Pharmacokinetics and Safety of Padsevonil

Pharmacokinetics

United Kingdom
UCB Biopharma S.P.R.L.

Completed

A Study to Test the Safety and Tolerability of Single and Multiple Doses of Padsevonil in Adult and Elderly Study Participants

Elderly Study Participants | Adult Study Participants

United States
UCB Biopharma S.P.R.L.

Terminated

A Study to Test the Pharmacodynamic, Pharmacokinetic, Safety, and Tolerability of Padsevonil in Healthy Study Participants Receiving Either Ethanol or Cannabidiol

Healthy Participants

Netherlands
UCB Biopharma S.P.R.L.

Completed

A Study to Test the Safety, Tolerability, and Pharmacokinetics of UCB0599 in Healthy Study Participants and Patients With Parkinson's Disease (PD)

Parkinson's Disease

United States
UCB Biopharma S.P.R.L.

Completed

A Study to Assess the Efficacy and Safety of Brivaracetam as Treatment for Increased Seizure Activity in an Epilepsy Monitoring Unit Setting

Epilepsy

United States
UCB Biopharma S.P.R.L.

Completed

A Study to Compare the Blood Level of Bimekizumab Injected Subcutaneously Either by a Prefilled Syringe or by an Auto-injector in Adult Healthy Volunteer Participants

Healthy Volunteers

United States, Germany
UCB Biopharma S.P.R.L.

Completed

A Study to Test the Safety and Tolerability and Pharmacokinetics of Single Doses of UCB0107 in Healthy Japanese Subjects

Healthy Japanese Volunteers

United Kingdom
UCB Biopharma S.P.R.L.

Completed

A First-In-Human Study With a Single Dose UCB4019 in Healthy Volunteers

Healthy Volunteers

United Kingdom
River Pharma S.r.l.

Completed

Clinical Trial to Evaluate the Effects of a Nutraceutical in Patients Affected by Knee Osteoarthritis (SMILE)

Knee Osteoarthritis

Romania
UCB Biopharma S.P.R.L.
Parexel

Completed

A Clinical Study to Investigate the Long-term Use of Lacosamide as Monotherapy in Subjects Who Completed Study SP0994

Epilepsy

Bulgaria, Finland, France, Germany, Japan, Korea, Republic of, Latvia, Mexico, Philippines, Poland, Romania, Russian Federation, Sweden, Switzerland, Ukraine
UCB Biopharma S.P.R.L.
Parexel

Completed

Study to Evaluate Safety and Efficacy of Different Doses of Bimekizumab in Patients With Chronic Plaque Psoriasis (BE ABLE 1)

Chronic Plaque Psoriasis

United States, Canada, Czechia, Hungary, Japan, Poland
UCB Biopharma S.P.R.L.
Parexel

Completed

A Study to Assess the Effectiveness of Certolizumab Pegol in Patients With Axial Spondyloarthritis in Daily Life (CIMAX)

Axial Spondyloarthritis

Belgium, Germany, Greece, Italy, Spain, United Kingdom
UCB Biopharma S.P.R.L.
PRA Health Sciences

Completed

Evaluating the Effectiveness of Neupro® (Rotigotine) and L-dopa Combination Therapy in Patients With Parkinson's Disease (NEUPART)

Idiopathic Parkinson's Disease

Germany, France, Italy, Spain, United Kingdom
UCB Biopharma S.P.R.L.
PRA Health Sciences

Completed

A Study of UCB0942 in Adult Patients With Highly Drug-resistant Focal Epilepsy

Highly Drug-resistant Focal Epilepsy

Belgium, Bulgaria, Germany, Hungary, Netherlands, Spain

3

Subscribe